Abbonarsi

Molecular and immunophenotypic profiling of leukemia cutis in acute myeloid leukemia: A retrospective matched-cohort study - 18/09/25

Doi : 10.1016/j.jaad.2025.05.1414 
Grant Z. Zhao, BA a, Samantha Guhan, MD a, b, Walter J. Liszewski, MD a, b, Cuong V. Nguyen, MD a, b,
a Northwestern University, Feinberg School of Medicine, Chicago, Illinois 
b Department of Dermatology, Northwestern University, Chicago, Illinois 

Correspondence to: Cuong V. Nguyen, MD, Department of Dermatology, Northwestern University, Feinberg School of Medicine, 676 N St Clair St, Ste 1600, Chicago, IL 60611.Department of DermatologyNorthwestern UniversityFeinberg School of Medicine676 N St Clair StSte 1600ChicagoIL60611

Abstract

Background

Leukemia cutis (LC) is a rare complication of acute myeloid leukemia (AML) and considered a marker of poor prognosis. Molecular and immunophenotypic characteristics of LC remain poorly understood.

Objective

To investigate molecular and immunophenotypic profiles of AML patients with LC and compare them with AML patients without LC.

Methods

This retrospective matched-cohort study examined 47 AML patients with LC propensity-matched to 141 AML patients without LC. Frequency of mutations, overall survival, and biomarker concordance between skin and bone marrow samples were analyzed and compared.

Results

LC patients showed significant enrichment in mutations including NPM1, FLT3, Trisomy/Gain 8, and NRAS/KRAS. Median overall survival for LC patients was 14.6 months, compared to 23.0 months for AML patients without LC. This difference was not statistically significant, and there were no significant differences when comparing across mutation subgroups. Immunophenotypically, high rates of discordance between skin and bone marrow were observed in CD34 and CD117.

Limitations

Single-center study, limited sample size, and potential unadjusted covariates.

Conclusion

The results show enrichment of key mutations and loss of biomarker expression in AML-associated LC without differences in overall survival. This distinct molecular and immunophenotypic profile of LC may have important pathogenic, diagnostic, and prognostic implications.

Il testo completo di questo articolo è disponibile in PDF.

Key words : acute myeloid leukemia, genotype, immunophenotype, leukemia cutis, molecular, mutation

Abbreviations used : AML, IHC, LC


Mappa


 Funding sources: None.
 Patient consent: Not applicable.
 IRB approval status: This study was approved by the Northwestern University Feinberg School of Medicine and Ann & Robert H. Lurie Children's Hospital of Chicago Institutional Review Boards.
 Cuong V. Nguyen had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.


© 2025  American Academy of Dermatology, Inc.. Pubblicato da Elsevier Masson SAS. Tutti i diritti riservati.
Aggiungere alla mia biblioteca Togliere dalla mia biblioteca Stampare
Esportazione

    Citazioni Export

  • File

  • Contenuto

Vol 93 - N° 4

P. 988-992 - ottobre 2025 Ritorno al numero
Articolo precedente Articolo precedente
  • Safety and efficacy of topical simvastatin plus cholesterol cream versus topical simvastatin cream alone for porokeratosis ptychotropica: A randomized, single-blind, split-body, placebo-controlled, investigator-initiated trial
  • Zhiming Chen, Yihe Liu, Hui Yu, Jing Li, Xin Huang, Ruiyu Xiang, Ran Mo, Hao Chen, Yong Yang
| Articolo seguente Articolo seguente
  • Antidepressant usage and its postoperative outcomes on the surgical management of basal cell carcinomas: A propensity-matched cohort analysis
  • Nehaa Sohail, Ayaan Sohail, Amir Alsaidi, Matthew Dallo, Misha V. Koshelev

Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.

Già abbonato a @@106933@@ rivista ?

@@150455@@ Voir plus

Il mio account


Dichiarazione CNIL

EM-CONSULTE.COM è registrato presso la CNIL, dichiarazione n. 1286925.

Ai sensi della legge n. 78-17 del 6 gennaio 1978 sull'informatica, sui file e sulle libertà, Lei puo' esercitare i diritti di opposizione (art.26 della legge), di accesso (art.34 a 38 Legge), e di rettifica (art.36 della legge) per i dati che La riguardano. Lei puo' cosi chiedere che siano rettificati, compeltati, chiariti, aggiornati o cancellati i suoi dati personali inesati, incompleti, equivoci, obsoleti o la cui raccolta o di uso o di conservazione sono vietati.
Le informazioni relative ai visitatori del nostro sito, compresa la loro identità, sono confidenziali.
Il responsabile del sito si impegna sull'onore a rispettare le condizioni legali di confidenzialità applicabili in Francia e a non divulgare tali informazioni a terzi.


Tutto il contenuto di questo sito: Copyright © 2026 Elsevier, i suoi licenziatari e contributori. Tutti i diritti sono riservati. Inclusi diritti per estrazione di testo e di dati, addestramento dell’intelligenza artificiale, e tecnologie simili. Per tutto il contenuto ‘open access’ sono applicati i termini della licenza Creative Commons.